L-DOPA

• CAT Number: A000350
• CAS Number: 59-92-7
• Purity: ≥95%
• Synonyms: (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid
• InChI: InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1
• InChIKey: WTDRDQBEARUVNC-LURJTMIESA-N
• SMILES: C1=CC(=C(C=C1CC(C(=O)O)N)O)O

L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson’s disease[1][2][3].
L-DOPA can be used in animal modeling to construct a rat model of dyskinesia.
L-DOPA (20 mg/kg; oral) reduces Rotenone-induced motor dysfunction[3].
L-DOPA (10, 30, 50, 70, and 100 mg/kg; oral) reverses tactile, cold and heat allodynia in neuropathic rat without any side effect in sprague-Dawley rats[4].In adult common marmosets (Callithrix jacchus, 2-3 years old, 270-350 g), L-DOPA (20/5 mg/kg, p.o.) shows the Tmax was 30 min in plasma and 60-90 min in extracellular fluid (ECF) of striatum. Mean Cmax was 20.3 μM in plasma and 442.9 nM in ECF of striatum, which is about 2.2% of that in plasma[6].
Induction of dyskinesia model[5]
Background

L-DOPA-induced dyskinesia results from a pulsatile stimulation of brain dopamine (DA) receptors, triggering a complex cascade of molecular and synaptic alterations within the basal ganglia[5].
Specific Mmodeling Methods

Mice: C57Bl/6 mice?•?male?• 8 weeks (period: 21 days)Administration: 20 mg/kg?•?ip?•?once daily for 21 days

Note

(1) sustained unilateral 6-OHDA injections in the striatum before starting treatment.
(2) Injection volume is 10mL/kg body weight.
Modeling Indicators

Behavioral changes: Shows developed abnormal involuntary movements (AIMs) affecting the head, trunk and forelimb on the side contralateral to the lesion.
Correlated Product(s): Oxidopamine hydrochloride (HY-B1081)
Opposite Product(s): Oxidopamine hydrobromide (HY-B1081A)